Related Experiment Video
Updated: Jun 11, 2025

03:14
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
Published on: December 6, 2024
510
Closing the gap between open-source and commercial large language models for medical evidence summarization
Gongbo Zhang1, Qiao Jin2, Yiliang Zhou3
1Department of Biomedical Informatics, Columbia University, New York, NY, USA.
Arxiv
|October 7, 2024
Summary
Fine-tuning open-source large language models (LLMs) significantly enhances their ability to summarize medical evidence. This approach improves transparency and performance, making them competitive with proprietary models.
Area of Science:
- Artificial Intelligence
- Natural Language Processing
- Medical Informatics
Background:
- Large language models (LLMs) show potential for summarizing medical evidence.
- Proprietary LLMs offer high performance but lack transparency and create vendor dependency.
- Open-source LLMs provide transparency and customization but generally underperform proprietary models.
Purpose of the Study:
- To evaluate the effectiveness of fine-tuning open-source LLMs for medical evidence summarization.
- To determine if fine-tuning can bridge the performance gap between open-source and proprietary LLMs.
Main Methods:
- Utilized the MedReview benchmark dataset (8,161 systematic review-summary pairs).
- Fine-tuned three open-source LLMs: PRIMERA, LongT5, and Llama-2.
- Evaluated performance using ROUGE-L, METEOR, and CHRF scores, alongside human and GPT-4 simulated evaluations.
Main Results:
- Fine-tuned LLMs showed significant improvements: +9.89 ROUGE-L, +13.21 METEOR, +15.82 CHRF.
- Fine-tuned LongT5 approached GPT-3.5 performance in zero-shot settings.
- Smaller fine-tuned models sometimes outperformed larger zero-shot models.
- Performance gains were consistent across automated and human evaluations.
Conclusions:
- Fine-tuning substantially boosts open-source LLM performance for medical evidence summarization.
- This approach offers a viable, transparent alternative to proprietary models.
- Results guide the selection of LLMs for specialized tasks like medical evidence synthesis.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Genomics
36.2K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
36.2K
Pharmacokinetic Models: Overview
607
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
607
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Bioequivalence: Overview
935
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
935
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K

